Verona Pharma plc
VRNA
Ранг среди акций
#2232
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Цена акции
$106.91
Последняя синхронизация: 2025-10-07
Рыночная капитализация
$9.09B
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
GB
Торговля Verona Pharma plc (VRNA)
Категория
Healthcare
Количество находящихся в обращении акций Verona Pharma plc (VRNA)
Количество акций в обращении на June 2025: 85.64M
Согласно последним финансовым отчетам и цене акций Verona Pharma plc, текущее количество акций в обращении составляет 85.64M. На конец December 2023 у компании было 75.51M акций в обращении. Количество акций в обращении обычно зависит от сплитов и обратного выкупа акций.
История количества акций в обращении Verona Pharma plc (VRNA) с 2005 по 2026
Акции в обращении на конец каждого года
| Год | Акции в обращении | Изменить |
|---|---|---|
| 2026 (TTM) | 85.64M | 6.67% |
| 2024 | 80.29M | 6.32% |
| 2023 | 75.51M | 14.31% |
| 2022 | 66.06M | 11.68% |
| 2021 | 59.15M | 79.97% |
| 2020 | 32.87M | 149.64% |
| 2019 | 13.17M | 0.21% |
| 2018 | 13.14M | 19.79% |
| 2017 | 10.97M | 161.94% |
| 2016 | 4.19M | 65.85% |
| 2015 | 2.52M | 16.52% |
| 2014 | 2.17M | 154.03% |
| 2013 | 853.00K | 11.28% |
| 2012 | 766.55K | -0.19% |
| 2011 | 768.03K | 0.00% |
| 2010 | 768.03K | 0.00% |
| 2009 | 768.03K | 0.00% |
| 2008 | 768.03K | 0.00% |
| 2007 | 768.03K | 0.00% |
| 2006 | 768.03K | 0.00% |
| 2005 | 768.03K | 0.00% |
Акции в обращении у аналогичных компаний или конкурентов
| Компания | Акции в обращении | Разница | Страна |
|---|---|---|---|
| 253.90M | 196.46% |
US
|
|
| 396.00M | 362.37% |
US
|
|
| 478.91M | 459.18% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -27.39% |
NL
|
